The US will share up to 60 million doses of its AstraZeneca vaccine with other countries as they become available, the White House has said.
Health authorities have a stockpile of the vaccine even though US regulators have not yet authorised it for public use. The doses will be exportable over the coming months after a federal safety review.
Critics have accused the government of hoarding the vaccine while other countries are in desperate need, the BBC is reporting.
Last month President Joe Biden pledged to share about four million doses of the AstraZeneca vaccine with Mexico and Canada – both of which have approved the jab.
The crisis in India has also piled pressure on the Biden administration to share US health resources.
On Monday, the White House said it expected that about 10 million doses of the AstraZeneca vaccine could be released when the Food and Drug Administration (FDA) finishes its review in the coming weeks.
It said that another 50 million doses were in various stages of production.
At a news briefing, White House spokesman Jen Psaki said FDA officials would carry out quality checks on doses before they were exported.
“Our team will share more details about our planning and who will be receiving offers from here, but we’re in the planning process at this point in time,” she added.
The US has already announced that it will provide raw materials for Indian vaccine manufacturers as the country battles a devastating surge in cases.
In a “warm and positive” phone call with Indian Prime Minister Narendra Modi on Monday, Biden promised more emergency assistance “including oxygen-related supplies, vaccine materials and therapeutics”, a White House statement said.
Washington is also looking at supplying oxygen, Covid tests, personal protective equipment and the antiviral drug remdesivir to India’s health service.
The FDA has so far authorised three vaccines against Covid-19: Pfizer BioNTech, Moderna and Johnson & Johnson. Experts say it looks likely that these will provide all the country’s needs and the AstraZeneca jab may be surplus.
According to the latest figures, more than 53% of adults have so far received at least one dose of vaccine.
The biggest job ahead for the administration will be convincing anti-vax Americans to get the increasingly available jabs.